SAN ANTONIO (PRWEB) December 02, 2017 -- Brain Sentinel, Inc., a Texas company, has purchased the assets of IctalCare A/S, a Danish company. These assets include intellectual property, and a non-prescription, wearable device designed to monitor for seizure activity.
"We are excited to add to our product line a small, wearable surface electromyography (sEMG) monitor that consumers may order and use without a prescription," said Mike Girouard, President, CEO, and co-founder of Brain Sentinel, Inc. Girouard continued, “With this acquisition, Brain Sentinel can now offer a more complete line of technology for epilepsy patients--an FDA cleared, prescription diagnostic system for physician use, and now a seizure monitor for real time notification of seizure-like activity for non-prescription consumer use.”
ABPN board-certified epileptologist and Brain Sentinel co-founder, José E. Cavazos, MD, PhD, added, "This new seizure monitor is designed to help allay the worry around a loved one with epilepsy. We started our journey at Brain Sentinel with parents in mind who struggle sleeping at night, living in fear of their son or daughter’s nocturnal seizures.” It will be available for sale directly to consumers, without a prescription, through Brain Sentinel’s website (http://brainsentinel.com) mid-year 2018.
Brain Sentinel will also have the opportunity to work with Isa Conradsen, Ph.D., formerly with IctalCare. Dr. Conradsen has been prolific in publishing articles in peer reviewed journals regarding the sEMG of seizures, and the IctalCare designed product. Her work has been published in Epilepsia, Annals of Neurology, Clinical Neurophysiology, Epilepsy Research, and through the IEEE.
About Brain Sentinel and the SPEAC® System
Brain Sentinel, Inc. is a privately held medical device start-up based in San Antonio, Texas. The company manufactures and markets its sEMG-based System under the name, the SPEAC® System: the Sensing, Portable sEMG, Analysis and Characterization System. Brain Sentinel is committed to helping people gain better control over their seizures and be heard by their physicians.
The SPEAC® System is the first and only FDA cleared, sEMG monitor to analyze sEMG signals that may be associated with generalized tonic-clonic (GTC) seizures, and to provide an alarm in 5.3 seconds on average, to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional. It is available only by prescription.
Jeff Jung, Brain Sentinel, Inc, http://BrainSentinel.com, +1 2109518696, [email protected]
SOURCE Brain Sentinel, Inc